Literature DB >> 12928120

Multiple suspicious lesions detected by autofluorescence bronchoscopy predict malignant development in the bronchial mucosa in high risk patients.

Arifa Pasic1, Anton Vonk-Noordegraaf, Elle K J Risse, Pieter E Postmus, Tom G Sutedja.   

Abstract

Autofluorescence bronchoscopy (AFB) has been shown to be sensitive to detect preneoplastic lesions in central airways. Apart from bronchial mucosa thickness, tissue autofluorescence is also related to the biochemical properties of the target cells. Genetic studies have shown molecular abnormalities to be present in histologically normal mucosal specimens. Forty-six high-risk individuals, free of micro-invasive cancer at the initiation of the study, were included in this analysis and have been subjected to repeat bronchoscopic examinations every 4-6 months. They had previous curatively treated lung cancer (n=18), ENT tumor (n=11) or were at risk to acquire lung cancer primaries (n=17). Baseline AFB is scored for each suspicious lesion, thus the total score represents the number of AFB suspicious lesions present in each individual at risk. Baseline AFB score was correlated to outcome, i.e. the development of squamous-cell cancer (SCC) in each individual. So far, 11/46 (24%) of the individuals acquired SCC. Follow up has been 12-80 months. All five individuals with >/=3 lesions (100%, 12-36 months), five of the ten (50%, 12-48 months) individuals who had two lesions and one among the 12 (8%, 36 months) individuals with one suspicious AFB lesion, developed SCC. Up till now (12-80 months), the remaining 19 individuals without any suspicious AFB lesion have not acquired SCC. The average AFB score for the group of individuals which developed SCC was significantly different (P<0.001) from the remaining individuals who did not acquire SCC (2.64+/-1.1 vs. 0.6+/-0.7 S.D.). The number of suspicious lesions at baseline AFB is a good predictor for the development of SCC in the individuals at risk in our study population. This finding is compatible with field carcinogenesis and warrants a more upfront use of AFB in a lung cancer screening to sift the different risk-cohorts in a population mainly at risk for developing metachronous lung cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12928120     DOI: 10.1016/s0169-5002(03)00191-0

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Preinvasive Endobronchial Lesions: Lung Cancer Precursors and Risk Markers?

Authors:  Stephen Lam; Eva Szabo
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

2.  Detection and minimally invasive treatment of early squamous lung cancer.

Authors:  Johannes M A Daniels; Thomas G Sutedja
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

3.  Autofluorescence-guided surveillance for oral cancer.

Authors:  Vijayvel Jayaprakash; Maureen Sullivan; Mihai Merzianu; Nestor R Rigual; Thom R Loree; Saurin R Popat; Kirsten B Moysich; Soumya Ramananda; Timothy Johnson; James R Marshall; Alan D Hutson; Thomas S Mang; Brian C Wilson; Steven R Gill; Jennifer Frustino; Arjen Bogaards; Mary E Reid
Journal:  Cancer Prev Res (Phila)       Date:  2009-11

4.  A case of primary non-small cell lung cancer with synchronous small cell lung cancer.

Authors:  Hanli Wang; Zhiwei Lu
Journal:  Mol Clin Oncol       Date:  2016-04-19

5.  Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.

Authors:  Daniel T Merrick; Dexiang Gao; York E Miller; Robert L Keith; Anna E Baron; William Feser; Timothy C Kennedy; Patrick J Blatchford; Sarah Braudrick; Fred R Hirsch; Lynn Heasley; Paul A Bunn; Wilbur A Franklin
Journal:  Cancer Prev Res (Phila)       Date:  2015-11-05

6.  Phenotype-genotype correlation in multiple primary lung cancer patients in China.

Authors:  Yang Yang; Wei Yin; Wenxin He; Chao Jiang; Xiao Zhou; Xiao Song; Junjie Zhu; Ke Fei; Weijun Cao; Gening Jiang
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.